Related Experiment Video

Updated: Mar 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

[Management and treatment of patients with hepatitis B]

Eva Van den Eynde1, Mar Riveiro-Barciela2

  • 1Unidad VIH, Servicio de Enfermedades Infecciosas, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.

Enfermedades Infecciosas Y Microbiologia Clinica
|July 31, 2016
PubMed

Insights

Chronic hepatitis B affects millions globally. Current therapies aim to suppress viral replication, with tenofovir and entecavir emerging as preferred first-line treatments due to efficacy and safety.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Chronic hepatitis B virus (HBV) infection is a significant global health issue, impacting approximately one-third of the world's population.
  • Over 350 million individuals are chronic HBV surface antigen carriers, facing risks of severe liver disease.
  • Therapeutic goals include preventing liver fibrosis, cirrhosis, and hepatocarcinoma through sustained viral replication suppression.

Purpose of the Study:

  • To review current therapeutic strategies for chronic hepatitis B.
  • To evaluate the efficacy and safety profiles of available treatments.
  • To identify optimal first-line therapies for managing chronic HBV infection.

Main Methods:

  • Review of current treatment guidelines and clinical trial data for chronic hepatitis B.
  • Comparison of pegylated interferon and nucleoside/nucleotide analogue therapies.
  • Assessment of viral suppression, adverse events, and resistance profiles.

Main Results:

  • Pegylated interferon offers limited duration therapy but has drawbacks in adverse events and administration.
  • Nucleoside/nucleotide analogues are widely used for long-term management.
  • Tenofovir and entecavir demonstrate potent HBV inhibition with high genetic barriers to resistance and favorable safety profiles.

Conclusions:

  • Tenofovir and entecavir are considered first-line therapies for chronic hepatitis B.
  • These agents offer effective viral suppression with minimal adverse effects.
  • Sustained suppression of HBV replication is crucial for preventing long-term liver complications.

Keywords:
Carcinoma hepatocelularChronic hepatitis BCirrosis hepáticaEntecavirHepatitis B crónicaHepatocellular carcinomaInferferonInterferónLiver cirrhosisTenofovirTratamientoTreatment

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
730
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
737
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
313
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.0K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
457